Abstract 5058
Background
Caregiving a cancer patient is a complex role that involves new responsibilities for which caregivers don’t feel ready to provide care. Caregivers who feel unprepared for giving care have physical, psychological and social problems. It is necessary to determine all the needs of caregivers.
Methods
This is cross-sectional descriptive study was carried out with 203 Turkish cancer family caregivers at the oncology wards of six hospital from January-March 2019. We defined a caregiver as one of the family members who give most assistance. Data were collected with “Preparedness Scale of the Family Care Inventory”. The scale consists of eight items, total score range is 0-32. Higher scores indicate that the caregiver feels more prepared for their role. Data were evaluated by independent groups t test, one-way analysis of variance test.
Results
The mean age of the caregivers was 46.8±13.8; most of them were female (64.5%); 68% of them felt constantly tired during the caregiving period; 55% had a decrease in social relations. Seventy one percent of the caregivers expressed that they wanted to know about the practices to protect their patients from infection; 64% of them wanted to know about what to do in case of emergency. Caregivers’ mean score from the scale was 27.0±6.0. Preparedness scores of those with high socioeconomic status are higher than those with low socioeconomic status (F = 4.047; p = 0.001). Less than one-year caregivers are more ready to provide care than caregivers for between one-five years; and between six-ten years caregivers are more ready to provide care than between one-five years (F = 6.464; p = 0.002).
Conclusions
Meeting caregiving needs is associated with high socioeconomic status. It is expected result that high socioeconomic status is related to preparedness for caregiving. Less than one-year caregivers encounter less problems. Nurses need to recognize that ’new’ cancer caregivers may be feeling difficulty when the problem is encountered. Caregivers with more experience duration develop the ability to solve care problems as the time to care for cancer patients increases. Nurses need to recognize that caregivers often are ’experienced’ caregivers may be feeling burnout and ignore their own health-related problems.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract